Updates are available Correction dated 2024-12-11
Click to view Correction: https://doi.org/10.1186/s13063-024-08686-6
-
Authors
Zhang, Yiqun https://orcid.org/0009-0000-5811-4439
Liu, Rong
Zhao, Yangyang
Wang, Zhiyan
Wang, Chi
Li, Qiang
Han, Dorothy
Anderson, Craig S.
Du, Xin https://orcid.org/0000-0002-7463-8707
Dong, Jianzeng
- License Information
-
More Information
Article History
Received: 24 May 2024
Accepted: 4 September 2024
First Online: 25 November 2024
Change Date: 11 December 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13063-024-08686-6
Declarations
:
: This trial received approval from the Clinical Research Ethics Committee at Beijing Anzhen Hospital (Research Ethics Review (2021) No.18). Prior to participation, all subjects and/or their legal guardian(s) will provide informed consent. The study will be conducted in accordance with the protocol, applicable regulatory requirements, and the ethical principles of the Declaration of Helsinki as adopted by the 18th World Medical Assembly in Helsinki, Finland, in 1964 and subsequent versions.
: Not applicable.
: The PANDA II main trial is an academic study conceived and conducted by cardiovascular interventionalists in academic research institutions. Study logistics, handling of data, and statistical assessments will be financed by the HHRC, Beijing, China. The steering committee will apply for grants from public funds and from the manufacturer of the influenza vaccine used in the study. Possible external sponsors will have no influence on the conduct of the study. The authors declare that they have no other competing interests.
